Abstract
Studies to date confirm that troglitazone has therapeutic benefits to NIDDM and can normalize IGT in those individuals at increased risk of developing NIDDM. Hyperinsulinaemia is reduced by such treatment in association with reduced insulin resistance and there are favourable effects on blood pressure with troglitazone therapy as well. Since insulin resistance and hyperinsulinaemia are usually present in obesity and impaired glucose tolerance (IGT), troglitazone may be useful in preventing the development of NIDDM in these susceptible populations.
MeSH terms
-
Animals
-
Blood Glucose / metabolism*
-
Blood Pressure / drug effects
-
Chromans / adverse effects
-
Chromans / therapeutic use*
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / physiopathology
-
Glucose Intolerance / drug therapy*
-
Glucose Tolerance Test
-
Humans
-
Hyperinsulinism
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Insulin Resistance*
-
Obesity / drug therapy*
-
Thiazoles / adverse effects
-
Thiazoles / therapeutic use*
-
Thiazolidinediones*
-
Troglitazone
Substances
-
Blood Glucose
-
Chromans
-
Hypoglycemic Agents
-
Thiazoles
-
Thiazolidinediones
-
Troglitazone